However, the higher-efficacy treatments (such as Ocrevus and Alemtuzumab) were not included in that research analysis. Ongoing research is looking at the effectiveness and safety of aHSCT therapy ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments ...

There are many treatments available for MS, many of which can help decrease the frequency and severity of relapses, improve physical function, and ease symptoms caused by the condition. While ...

Ozanimod▼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features. Ozanimod® is subject to ...

Summary of Infused DMTs DMT How It's Taken Common Side Effects Lemtrada (alemtuzumab) Infused for five days in a row for the first treatment course and then for three days in a row about one year ...

We would like to use cookies to collect information about how you use ons.gov.uk. We use this information to make the website work as well as possible and improve our services.

The CELESTIAL-301 trial evaluating SynKIR-310, a novel CAR T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma.